NASDAQ:INSM - Insmed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.43
  • Forecasted Upside: 43.59 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$37.21
▼ -2.82 (-7.04%)
1 month | 3 months | 12 months
Get New Insmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INSM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$53.43
▲ +43.59% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $53.43, with a high forecast of $60.00 and a low forecast of $44.00. The average price target represents a 43.59% upside from the last price of $37.21.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Insmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2021Credit Suisse GroupBoost Price TargetOutperform$50.00 ➝ $60.00High
i
1/4/2021SVB LeerinkBoost Price TargetOutperform$51.00 ➝ $55.00N/A
i
12/17/2020Berenberg BankInitiated CoverageBuy$48.00Medium
i
12/16/2020Morgan StanleyBoost Price TargetOverweight$42.00 ➝ $55.00High
i
11/23/2020Evercore ISIReiterated RatingOutperform$60.00Low
i
11/11/2020Morgan StanleyBoost Price TargetOverweight$38.00 ➝ $42.00High
i
10/12/2020Stifel NicolausInitiated CoverageBuy$44.00Medium
i
8/10/2020Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $38.00Medium
i
6/25/2020HC WainwrightReiterated RatingBuy$52.00High
i
Rating by Andrew Fein at HC Wainwright
5/1/2020HC WainwrightReiterated RatingBuy$52.00High
i
Rating by Andrew Fein at HC Wainwright
4/15/2020Morgan StanleyLower Price TargetOverweight$50.00 ➝ $35.00Low
i
Rating by Matthew Harrison at Morgan Stanley
3/17/2020Stifel NicolausLower Price TargetBuy$55.00 ➝ $45.00High
i
3/17/2020Credit Suisse GroupLower Price TargetOutperform$49.00 ➝ $42.00Medium
i
2/4/2020HC WainwrightReiterated RatingBuy$52.00Medium
i
Rating by Andrew Fein at HC Wainwright
2/4/2020The Goldman Sachs GroupBoost Price TargetBuy$33.00 ➝ $46.00High
i
2/4/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $50.00High
i
Rating by Matthew Harrison at Morgan Stanley
1/15/2020JMP SecuritiesReiterated RatingBuy$40.00High
i
Rating by Liisa Bayko at JMP Securities
1/6/2020CowenReiterated RatingBuy$56.00High
i
1/2/2020Credit Suisse GroupReiterated RatingOutperform$40.00 ➝ $40.00Medium
i
1/2/2020Canaccord GenuityInitiated CoverageBuy$20.00Medium
i
11/1/2019Morgan StanleySet Price TargetBuy$37.00Low
i
Rating by Matthew Harrison at Morgan Stanley
10/31/2019HC WainwrightReiterated RatingBuyLow
i
Rating by A. Fein at HC Wainwright
9/10/2019Credit Suisse GroupReiterated RatingBuy$40.00Medium
i
9/3/2019The Goldman Sachs GroupInitiated CoverageBuy$30.00High
i
4/9/2019HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $52.00Medium
i
3/8/2019Canaccord GenuitySet Price TargetBuy$32.00 ➝ $44.00Medium
i
2/15/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$40.00Medium
i
1/17/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$29.00 ➝ $35.00High
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
1/15/2019Canaccord GenuityBoost Price TargetBuy$20.00 ➝ $32.00High
i
1/2/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$20.00High
i
12/4/2018CitigroupLower Price TargetNeutral ➝ Neutral$29.00 ➝ $22.00High
i
10/1/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Buy$33.00 ➝ $35.00High
i
10/1/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $40.00High
i
9/19/2018The Goldman Sachs GroupSet Price TargetHold$25.00High
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
8/6/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformMedium
i
8/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $39.00High
i
8/3/2018HC WainwrightReiterated RatingBuy$43.00Low
i
Rating by A. Fein at HC Wainwright
7/23/2018The Goldman Sachs GroupInitiated CoverageNeutral$32.00Medium
i
4/23/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$27.00 ➝ $31.00High
i
3/21/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$39.00Medium
i
1/17/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$31.00Medium
i
1/4/2018HC WainwrightReiterated RatingBuy$35.00Medium
i
1/4/2018Robert W. BairdReiterated RatingOutperform ➝ Positive$32.00 ➝ $42.00High
i
Rating by Neena Bitritto-Garg at Robert W. Baird
11/6/2017HC WainwrightReiterated RatingBuy$35.00N/A
i
11/3/2017CowenReiterated RatingBuy$54.00N/A
i
9/6/2017CowenReiterated RatingOutperform$54.00High
i
9/6/2017Stifel NicolausReiterated RatingBuy$27.00 ➝ $43.00High
i
9/6/2017Robert W. BairdReiterated RatingOutperform ➝ Positive$23.00 ➝ $32.00High
i
Rating by Neena Bitritto-Garg at Robert W. Baird
9/6/2017HC WainwrightReiterated RatingBuy$35.00High
i
9/5/2017SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $36.00High
i
9/5/2017Evercore ISIBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $40.00High
i
Rating by Josh Schimmer at Evercore ISI
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$28.00Medium
i
8/2/2017HC WainwrightReiterated RatingBuyMedium
i
7/10/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$23.00Medium
i
6/11/2017CitigroupReiterated RatingNeutral$14.00 ➝ $17.00High
i
5/1/2017Stifel NicolausBoost Price TargetBuy$23.00 ➝ $27.00Medium
i
4/18/2017Stifel NicolausReiterated RatingBuy$23.00High
i
11/4/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
6/15/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
6/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
3/16/2016CitigroupLower Price TargetNeutral$21.00 ➝ $13.00N/A
i
3/15/2016Stifel NicolausInitiated CoverageBuy$23.00N/A
i
2/26/2016SVB LeerinkLower Price TargetOutperform$29.00 ➝ $23.00N/A
i
2/26/2016CowenReiterated RatingBuyN/A
i
(Data available from 2/25/2016 forward)
Insmed logo
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More

Today's Range

Now: $37.21
$37.01
$39.67

50 Day Range

MA: $39.35
$33.20
$44.30

52 Week Range

Now: $37.21
$12.09
$45.44

Volume

19,067 shs

Average Volume

820,141 shs

Market Capitalization

$3.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Insmed?

The following sell-side analysts have issued reports on Insmed in the last year: Berenberg Bank, Credit Suisse Group AG, Evercore ISI, HC Wainwright, Morgan Stanley, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for INSM.

What is the current price target for Insmed?

7 Wall Street analysts have set twelve-month price targets for Insmed in the last year. Their average twelve-month price target is $53.43, suggesting a possible upside of 33.5%. Evercore ISI has the highest price target set, predicting INSM will reach $60.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $44.00 for Insmed in the next year.
View the latest price targets for INSM.

What is the current consensus analyst rating for Insmed?

Insmed currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INSM will outperform the market and that investors should add to their positions of Insmed.
View the latest ratings for INSM.

What other companies compete with Insmed?

How do I contact Insmed's investor relations team?

Insmed's physical mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company's listed phone number is 908-977-9900 and its investor relations email address is [email protected] The official website for Insmed is www.insmed.com.